Inflammatory Bowel Disease

Telemedicine’s Past, Present and Future Role in Pediatric Inflammatory Bowel Disease Care
Telemedicine’s Past, Present and Future Role in Pediatric Inflammatory Bowel Disease Care 1024 683 Erin Gregory

A recent study sheds light on how telemedicine’s use during the pandemic has reshaped care delivery for children with IBD.   A recent study published in Journal of Pediatric Gastroenterology and Nutrition utilized electronic medical record data to compare the volume, duration and nature of office and telemedicine visits for pediatric patients with inflammatory bowel…

Infliximab Biosimilars Improve Growth Outcomes in Children With Inflammatory Bowel Disease
Infliximab Biosimilars Improve Growth Outcomes in Children With Inflammatory Bowel Disease 1024 683 Mary Bates, PhD

Treatment with either the infliximab originator or a biosimilar improves clinical and growth outcomes. In a new study, researchers at Nationwide Children’s Hospital report that children with inflammatory bowel disease showed similar growth and clinical outcomes whether they were treated with the infliximab originator or a biosimilar agent. The results add to the growing literature…

Improving the Diagnosis and Treatment of Iron Deficiency and Anemia in Children With Inflammatory Bowel Disease
Improving the Diagnosis and Treatment of Iron Deficiency and Anemia in Children With Inflammatory Bowel Disease 150 150 Lauren Dembeck

Iron deficiency with and without anemia is under-recognized and under-treated in children with inflammatory bowel disease.   Anemia is the most common extr-aintestinal manifestation of inflammatory bowel disease (IBD), which includes conditions such as Crohn’s disease and ulcerative colitis, and iron deficiency is the most prevalent cause of anemia in children with IBD. Several factors…

How Do Children With IBD and Their Caregivers Perceive Biosimilars?
How Do Children With IBD and Their Caregivers Perceive Biosimilars? 640 427 JoAnna Pendergrass, DVM

Many pediatric patients with inflammatory bowel disease and their caregivers are unaware of biosimilars, creating an opportunity for providers to educate patients and their families about this effective and less expensive treatment option. Infliximab is a biologic therapy that effectively manages inflammatory bowel disease (IBD) in adult and pediatric patients. However, biologic therapies are expensive,…

A Patient-Centered Medical Home for Pediatric Inflammatory Bowel Disease
A Patient-Centered Medical Home for Pediatric Inflammatory Bowel Disease 1024 683 Mary Bates, PhD

The Center for Pediatric and Adolescent IBD serves as a case study for comprehensive, multidisciplinary care. In a new paper published in Inflammatory Bowel Disease, researchers from Nationwide Children’s describe the multidisciplinary care model at the Center for Pediatric and Adolescent Inflammatory Bowel Disease as an example of a pediatric specialty medical home. The researchers…